SCHEMBL16670418

SCHEMBL16670418

C=CCOc1ccc(N(C)C(=O)C(Cc2ccccc2)NC(=O)NS(=O)(=O)c2ccccc2C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP9 P14780 2/20 0.43
MMP8 P22894 2/20 0.43
MMP1 P03956 1/20 0.43
MMP2 P08253 1/20 0.43
KDM1A O60341 1/20 0.39
MAOA P21397 1/20 0.39
KAT6A Q92794 2/20 0.37
NR3C1 P04150 1/20 0.37
GAA P10253 2/20 0.37
POLB P06746 1/20 0.36
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
BMP1 P13497 2/20 0.35
BCL2 P10415 1/20 0.35
F2 P00734 1/20 0.35
PRSS1 P07477 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16670416 1.00 MMP9 (0.43) MMP9MMP8MMP1MMP2KDM1A
SCHEMBL16681985 0.90 GAA (0.46) MMP9MMP8MMP1MMP2KDM1A
SCHEMBL18041029 0.90 GAA (0.46) MMP9MMP8MMP1MMP2KDM1A
SCHEMBL18057241 0.88 MMP9 (0.46) MMP9MMP8MMP1MMP2KDM1A
SCHEMBL16682022 0.88 MEN1 (0.38) MMP9MMP8MMP1MMP2KAT6A
SCHEMBL18041088 0.88 MEN1 (0.38) MMP9MMP8MMP1MMP2KAT6A
SCHEMBL16670299 0.88 FPR2 (0.47) MMP9MMP8MMP1MMP2KDM1A
SCHEMBL16670298 0.88 FPR2 (0.47) MMP9MMP8MMP1MMP2KDM1A
SCHEMBL16670249 0.87 MMP9 (0.45) MMP9MMP8MMP1MMP2KDM1A
SCHEMBL16670247 0.87 MMP9 (0.45) MMP9MMP8MMP1MMP2KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10035760-B2 Inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2018-07-31 US disclosed
US-10035760-B2 Inhibitors of human immunodeficiency virus replication VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2018-07-31 US disclosed
US-20160257645-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2016-09-08 US disclosed
EP-3060554-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION Bristol-Myers Squibb Company (US) 2016-08-31 EP disclosed
WO-2015061518-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2015-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160257645-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR1E, POLR1G MMP9 2601/4885MMP8 1726/4885MMP1 3144/4885
US-10035760-B2 Inhibitors of human immunodeficiency virus replication EIF2AK2, POLR1G, POLR1E MMP9 2622/4885MMP8 1954/4885MMP1 3205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.